Boston, MA, 07/01/2013 (financialstrend) – Immunomedics Inc. (NASDAQ:IMMU) had recently presented a company overview at the Wells Fargo Securities Conference held on June 19, 2013 at Boston, MA. The conference which witnessed the participation of wide range of companies targeting the audience group of investors belonging to different categories like venture capitalists, angel investors, institutional investors etc had provided Immunomedics Inc. (NASDAQ:IMMU) with an effective platform to discuss its corporate achievements.
Shares of Immunomedics Inc. (NASDAQ:IMMU) surged by 2.06 percent to close at $5.44 on Friday. The opening price for the stock was at $5.35 per share and thereafter fluctuated between $5.25 and $5.59 throughout the day. The 52 week low price of Immunomedics Inc. (NASDAQ:IMMU) is at $2.11 and 52 week high is readjusted to new value at $5.59 per share.
With around 82.72 million shares outstanding in the market, Immunomedics Inc. (NASDAQ:IMMU) presently has a market cap of $450 million. The company had witnessed the trade on 1.53 million shares on Friday, which was huge compared to the average trading volume at 927,111 shares per day. The institutional investors contribute to around 40 percent of the total capital of Immunomedics Inc. (NASDAQ:IMMU).
Immunomedics Inc. (NASDAQ:IMMU) is primarily involved in the research, development and commercialization of anti body based therapeutics for the treatment of different forms of cancer. The basic product categories of the pharmaceutical company are in three major areas. First product candidate is related to the in-vivo imaging products which are applied for the early detection and diagnosis of different forms of cancer using the new method called radio immuno detection method.
Second category of product involves the in-vitro diagnostic tests primarily applied for the detection of cancer and certain other categories of autoimmune diseases. The final product category of Immunomedics Inc. (NASDAQ:IMMU) is the in-vivo therapeutic products used for delivering the doses of gastrointestinal cancer tissues and radio isotopes colorectal drugs to the targeted parts.
